Health technology reviews

" "

Cardiac stents

Cardiac stents were first reviewed by the HTA program in 2009.

  • In 2015, the HCA director selected cardiac stents for re-review based on newly available evidence published since the 2009 assessment that could change the original coverage determination.
  • A re-review of cardiac stents was conducted in 2016.

Status: Decision completed.

View findings and decision 

Primary criteria ranking

  • Safety = High
  • Efficacy = High
  • Cost = Medium

Assessment timeline (2016)

  • ​​Draft key questions published: July 10, 2015
  • Public comment period: July 10 to 24, 2015
  • Final key questions published: August 31, 2015
  • Draft report published: October 20, 2015
  • Public comment period: October 20 to November 18, 2015
  • Final report published: December 14, 2015
  • HTCC public meeting: January 15, 2016

Background

The first aim of this assessment is to systematically review, critically appraise and analyze research evidence comparing the safety and efficacy of percutaneous coronary intervention with stenting (PCI) with medical therapy in patients with stable CAD. If there is evidence that PCI with stenting is more effective than medical therapy alone in preventing death or myocardial infarction (MI) and/or improving patient quality of life, the second aim is to update the 2009 HTA on coronary artery stenting by systematically reviewing, critically appraising and analyzing new research evidence comparing the safety and efficacy of percutaneous coronary intervention with newer generation FDA-approved drug eluting stents (DES) with bare metal stent (BMS).